Godfrey, Laura K.
Forster, Jan
Liffers, Sven-Thorsten
Schröder, Christopher
Köster, Johannes
Henschel, Leonie
Ludwig, Kerstin U.
Lähnemann, David
Trajkovic-Arsic, Marija
Behrens, Diana
Scarpa, Aldo
Lawlor, Rita T.
Witzke, Kathrin E.
Sitek, Barbara
Johnsen, Steven A.
Rahmann, Sven
Horsthemke, Bernhard
Zeschnigk, Michael
Siveke, Jens T.
Funding for this research was provided by:
Deutsche Forschungsgemeinschaft (LU-1944/3-1, SI1549/4-1)
Associazione Italiana per la Ricerca sul Cancro (12182, 12182)
Fondazione Cassa di Risparmio di Verona Vicenza Belluno e Ancona (203885/2017, 203885/2017)
Ministry of Science, North Rhine-Westphalia, Germany. (PURE)
German Federal Ministry of Education and Research (01KD2206A/SATURN3)
Ministry of Culture and Science of the State of North Rhine-Westphalia (research network CANcer TARgeting (CANTAR))
Universitätsklinikum Essen
Article History
Received: 19 September 2023
Accepted: 3 January 2024
First Online: 16 January 2024
Declarations
:
: For this study, already established patient-derived xenografts of pancreatic adenocarcinoma from three different male patients at passage number 2 were received from ARC-NET, University of Verona. The materials used have been collected under Program 1885 protocol 52438 on 23/11/2010 and Program 2172 protocol 26773CE 23/05/2012. The protocols include informed consent of the patients and were approved by the local ethics committee of the Integrated University Hospital Trust of Verona. All mice experiments were carried out by D. Behrens at EPO GmbH, Berlin-Buch, and performed according to the German Animal Protection Law with approval from the responsible authorities. The in vivo procedures were consistent and in compliance with the UKCCCR guidelines.
: Not applicable.
: J.T.S. receives honoraria as consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Immunocore, MSD Sharp Dohme, Novartis, Roche/Genentech, and Servier. His institution receives research funding from Abalos Therapeutics, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisbach Bio, and Roche/Genentech; he holds ownership and serves on the Board of Directors of Pharma15, all outside the submitted work.